How to Help Your Patients Find Hemgenix in Stock: A Provider's Guide

The March 2026 global stockout of Hemgenix (etranacogene dezaparvovec-drlb) has placed hemophilia treatment centers and prescribing hematologists in a challenging position: patients who have spent months preparing for this one-time gene therapy are now facing indefinite delays, while the eligibility work they have completed has a shelf life. This guide is designed to help providers manage patients actively waiting for Hemgenix, optimize their readiness for when supply returns, and communicate the situation clearly and compassionately.

Understanding the Hemgenix Distribution Model

Hemgenix is distributed exclusively to certified hemophilia treatment centers (HTCs) and qualified infusion sites. It is not stocked at retail or specialty pharmacies. CSL Behring ships patient-specific kits (weight-based, 2 mL/kg) directly to the treatment facility where the patient will receive infusion. For patients weighing 126–130 kg, the kit contains enough vials to deliver the full 2 × 10¹³ gc/kg dose.

Because each kit is patient-specific and generated from a manufacturing process that takes months, treatment centers cannot simply maintain a standing inventory of Hemgenix. Supply must be ordered in advance, tied to specific patients, and received within the appropriate handling and stability window.

Step 1: Establish Direct Communication With Your CSL Behring Representative

During the 2026 stockout, the most reliable source of supply information for your center is your dedicated CSL Behring medical affairs or field account representative. They can provide:

Region-specific supply status and estimated restoration timelines

Priority access protocols if your center has patients with urgent clinical need

Updated clinical support materials for patient communication

You can also reach HEMGENIX Connect at 1-833-436-0021 (M–F 8AM–8PM ET) for patient enrollment and case management support.

Step 2: Audit Your Patient Pipeline

Identify every patient in your Hemgenix pipeline and categorize by stage:

Stage 1 — Inquiry/evaluation: Encourage continued workup; prioritize inhibitor testing and liver baseline.

Stage 2 — Pre-screening complete, awaiting insurance PA: Submit PA immediately if not done; track expected approval date.

Stage 3 — PA approved, treatment not yet scheduled: Monitor authorization expiration; re-test any screening results approaching validity limits.

Stage 4 — Treatment date had been scheduled before stockout: Communicate directly, confirm nothing in their eligibility has changed, and maintain their position in the queue.

Step 3: Monitor Eligibility Test Validity Windows

Pre-treatment eligibility tests are time-limited and may need to be repeated if supply is not restored within certain windows. Specifically monitor:

Factor IX inhibitor titer: Should be confirmed negative (<0.6 Bethesda Units) before infusion. Re-test if prior results are >3 months old.

Liver function tests (ALT/AST): Baseline should be established shortly before infusion to allow accurate post-infusion monitoring.

Liver ultrasound: Required pre-treatment to assess hepatocellular carcinoma risk and baseline liver health.

AAV5 neutralizing antibody test: CSL Behring provides this test at no cost. The clinical significance of high titers remains an area of evolving research; note this data for each patient.

Step 4: Manage Insurance Authorizations Proactively

Hemgenix insurance prior authorization is managed under the medical benefit, not the pharmacy benefit. This means it goes through your facility's medical billing team, not a pharmacy benefit manager. Key considerations during the shortage:

Most commercial payers provide a 12-month authorization window — track expiration dates and begin renewal at 60–90 days out.

Medicare covers Hemgenix under Part B (outpatient medical infusion). Medicare Advantage plans may have separate prior authorization requirements.

Document all shortage-related delays in the medical record to support appeals if a payer attempts to deny renewal due to lack of administration.

How medfinder Can Support Your Team

medfinder is a service that contacts treatment centers and specialty pharmacies on behalf of patients to check medication availability, returning results by text. For patients willing to travel, this can be an effective way to identify which centers nationally have Hemgenix in stock. Encourage patients to visit medfinder.com/providers to learn how medfinder supports providers and patients navigating specialty medication access challenges.

See also our companion post: Hemgenix Shortage: What Providers and Prescribers Need to Know in 2026 for a clinical overview of the shortage situation.